SELLAS Life Sciences Group, Inc. (FRA:RXK3)
Germany flag Germany · Delayed Price · Currency is EUR
3.535
+0.030 (0.86%)
Last updated: Jan 20, 2026, 7:54 PM CET

FRA:RXK3 Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-25.94-30.88-37.34-41.3-20.7-16.76
Asset Writedown & Restructuring Costs
---105.7-
Stock-Based Compensation
1.881.562.091.731.010.58
Other Operating Activities
0.590.560.490.13-4.42-0.11
Change in Accounts Payable
-2.31-2.142.31.21-2.51-0.84
Change in Unearned Revenue
-----5.65.6
Change in Other Net Operating Assets
-4.84-4.511.044.430.51.11
Operating Cash Flow
-30.62-35.4-31.41-23.81-26.02-10.42
Sale (Purchase) of Intangibles
---5.5-4.5--
Investing Cash Flow
---5.5-4.5--
Issuance of Common Stock
31.9546.8222.3524.0812.0738.44
Repurchase of Common Stock
-0.06-0.06-0.03---
Financing Cash Flow
53.9146.7622.3224.0812.0738.44
Net Cash Flow
23.2911.36-14.6-4.23-13.9528.03
Free Cash Flow
-30.62-35.4-31.41-23.81-26.02-10.42
Free Cash Flow Margin
----2380.90%-342.38%-548.26%
Free Cash Flow Per Share
-0.33-0.58-1.13-1.23-1.68-1.31
Levered Free Cash Flow
-22.08-24.25-28.94-11.87-18.69-3.6
Unlevered Free Cash Flow
-22.08-24.25-28.94-11.87-18.69-3.6
Change in Working Capital
-7.15-6.653.355.64-7.625.87
Source: S&P Global Market Intelligence. Standard template. Financial Sources.